ArticleJournal of lipid research2019
Open access · hybridAbstract read
In one paragraph
Article in Journal of lipid research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- The Biology and Clinical Implications of PCSK7.Endocrine reviews · 2025Review
- Striving Towards Equity in Cardiovascular Genomics Research.Current atherosclerosis reports · 2025Review
- Association of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with non-alcoholic fatty liver disease and hepatic steatosis in United States adults: insights from NHANES 2017-2020.Frontiers in nutrition · 2025Article
- Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease.Frontiers in physiology · 2025Review
- PCSK7 levels in women with and without PCOS.Journal of clinical & translational endocrinology · 2024Article
- The contribution of genetics and epigenetics to MAFLD susceptibility.Hepatology international · 2024Review
- Oligonucleotide therapies for nonalcoholic steatohepatitis.Molecular therapy. Nucleic acids · 2024Review
- Leveraging the transcriptome to further our understanding of GWAS findings: eQTLs associated with genes related to LDL and LDL subclasses, in a cohort of African Americans.Frontiers in genetics · 2024Article
- Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.Frontiers in endocrinology · 2024Review
- Can Cardiometabolic Risk Be Reduced in the Elderly? Comprehensive Epidemiological Study.Geriatrics (Basel, Switzerland) · 2023Article
- Consensus Statement on the definition and classification of metabolic hyperferritinaemia.Nature reviews. Endocrinology · 2023Review
- Nonalcoholic fatty liver disease and non-liver comorbidities.Clinical and molecular hepatology · 2023Review
- Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis.Frontiers in endocrinology · 2023Article
- Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication.Journal of atherosclerosis and thrombosis · 2022Article
- Can PCSK7 be A New Pharmaceutical Target?Journal of atherosclerosis and thrombosis · 2022Article
- Post-Transcriptional Effects of miRNAs on PCSK7 Expression and Function: miR-125a-5p, miR-143-3p, and miR-409-3p as Negative Regulators.Metabolites · 2022Article
- Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease.Frontiers in pharmacology · 2022Article
- Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study.BMC gastroenterology · 2021Article
- Genetics Is of the Essence to Face NAFLD.Biomedicines · 2021Review
- The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin-Kexin Type 7 (Cells · 2021Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 9 institutions in 4 countries.
Paola DongiovanniGeneral Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Marica MeroniGeneral Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Guido BaselliDepartments of Pathophysiology and Transplantation Università degli Studi di Milano, Milan, Italy.
Rosellina M MancinaDepartment of Molecular and Clinical Medicine University of Gothenburg, Gothenburg, Sweden.
Massimiliano RuscicaPharmacological and Biomolecular Sciences Università degli Studi di Milano, Milan, Italy.
Miriam LongoGeneral Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Raffaela RamettaGeneral Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Annalisa CespiatiDepartments of Pathophysiology and Transplantation Università degli Studi di Milano, Milan, Italy.
Serena PelusiDepartments of Pathophysiology and Transplantation Università degli Studi di Milano, Milan, Italy.
Nicola FerriDipartimento di Scienze del Farmaco Università degli Studi di Padova, Padova, Italy.
Valeria RanzaniIstituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milan, Italy.
Valerio NobiliDepartment of Gastroenterology, Ospedale Bambin Gesù, Roma, Italy.
Jussi PihlajamakiDepartments of Medicine and Public Health and Clinical Nutrition University of Eastern Finland, and Clinical Nutrition and Obesity Center, Kuopio University Hospital, Kuopio, Finland.
Anna Ludovica FracanzaniGeneral Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Sara BadialiSurgery Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Salvatore PettaDepartment of Gastroenterology Universita di Palermo, Palermo, Italy.
Silvia FargionGeneral Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Stefano RomeoPharmacological and Biomolecular Sciences Università degli Studi di Milano, Milan, Italy.
Julia KozlitinaMcDermott Center for Human Growth and Development University of Texas Southwestern Medical Center, Dallas, TX.
Luca ValentiDepartments of Pathophysiology and Transplantation Università degli Studi di Milano, Milan, Italy luca.valenti@unimi.it.ORCID 0000-0001-8909-0345
University of Milan · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITIstituto Nazionale Genetica Molecolare · ITOspedale dei Bambini Vittore Buzzi · ITSouthwestern Medical Center · USUniversity of Eastern Finland · FIUniversity of Gothenburg · SEUniversity of Padua · ITUniversity of Palermo · IT
Funding
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5MNCATS NIH HHS UL1 TR001105
Abstract
Dyslipidemia and altered iron metabolism are typical features of nonalcoholic fatty liver disease (NAFLD). Proprotein convertase subtilisin/kexin type 7 (
Indexed as
AdultAnimalsCross-Sectional StudiesDyslipidemiasFemaleGenotypeHepatocytesHep G2 CellsHumansLinkage DisequilibriumLipogenesisMaleMetabolic DiseasesMiddle AgedNon-alcoholic Fatty Liver DiseaseSubtilisinsPCSK7 protein, humanSubtilisinsgenes in lipid dysfunctiongeneticsmetabolic diseasenonalcoholic fatty liver diseaseproprotein convertase subtilisin/kexin type 7
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.